Author Archives: William Looney

Typhoon Trauma: The Pharma Score on Disaster Relief

Big Pharma is quietly stepping up to provide critical supplies of essential medicines, other health equipment, and skilled local personnel to areas of the Philippines devastated by Typhoon Haiyan this month.  Although industry operations in the Philippines appear largely intact, most companies are working through global humanitarian aid organizations due to the logistical challenges created […]
Posted in Corporate Responsibility, Emerging Markets, Global | Tagged , , , , , , , | Leave a comment

Feds Take a Pass on Co-Pay Offsets Under Obamacare

Feds Take a Pass on Co-Pay Offsets Under Obamacare The implosion of the Affordable Care Act’s vaunted healthcare.gov benefit enrollment process has obscured a far more critical issue for big Pharma:  how much leeway do companies have in promoting durable brand affiliations among the potentially millions of new patients with subsidized access to new  medicines? […]
Posted in healthcare, Regulatory | Tagged , , , , , | Leave a comment

Putting a Price Tag on Compliance: Cheap Change or Big Bucks?

Compliance rules under the US Physician Payments Sunshine Act have been criticized for the excruciating level of detail demanded from individual company submissions.  But relatively little scrutiny has been accorded to another pressing question:  how much will all this new reporting cost?  The burden of compliance for not just this new law but in many […]
Posted in compliance, Marketing, Regulatory, Strategy | Tagged , , , , , | 1 Comment

Specialty Drugs: A Tempting Target, But What to Do?

A key issue for biopharma marketers today is balancing cost and value factors around specialty biologic drugs, particularly those for cancer and other high profile, life-altering diseases.  The financial and reputational stakes for players in this hotly contested commercial space are high, compounded by a startling lack of awareness of the incentives that drive specific […]
Posted in Biotech, Market Access, Meetings, pricing, Strategy | Tagged , , , , , , , , | Leave a comment

One Company, One Defining Moment

Being an observer rather than a participant in the drugs business makes it easier to sense those defining moments when something fundamental has changed, a limit is reached, and a new order emerges to reset the basic license to operate.   As Pharm Exec monthly goes to press, one such moment appears to have arrived, with […]
Posted in Emerging Markets, Global, Strategy | Tagged , , , , , , , , | 1 Comment
  • Categories

  • Meta